Table 4 Comparison between the intravenous non-high-dose and high-dose PPI after case-controlled matching for the subgroup of low risk patients (Rockall score < 6)
Characteristics | Non-high-dose Group (n = 27) | High-dose Group (n = 27) | p-value |
|---|---|---|---|
Age (years) | 65.8 ± 3.8 | 62.4 ± 14.7 | 0.991 |
Female gender, n (%) | 4(14.8) | 10(37.0) | 0.119 |
Creatinine(mg/dl) | 1.3 ± 0.5 | 1.5 ± 1.5 | 0.100 |
Hb (g/L) | 95.4 ± 25.1 | 106.0 ± 29.9 | 0.340 |
Platelets (× 109/L) | 202.2 ± 81.1 | 246.5 ± 91.6 | 0.151 |
Use of NSAIDs, n (%) | 3(11.1) | 5(18.5) | 0.704 |
Use of aspirin, n (%) | 2(7.4) | 1(3.7) | 1.000 |
Use of clopidogrel, n (%) | 1(3.7) | 2(7.4) | 1.000 |
Use of wafarin, n (%) | 1(3.7) | 3(11.1) | 0.610 |
Shock at presentation | 9(33.3) | 11(40.7) | 0.573 |
Coexisting illness, n (%) | Â | Â | Â |
CKD III, IV and V | 7(25.9)/0 | 7(25.9)/0 | 1.000 |
COPD | 1(3.7) | 0 | 1.000 |
CAD | 2(7.4) | 2(7.4) | 1.000 |
DM | 7(25.9) | 8(29.6) | 0.761 |
CVA | 3(11.1) | 5(18.5) | 0.704 |
Liver Cirrhosis | 1(3.7) | 1(3.7) | 1.000 |
Rockall score | 4.5 ± 0.6 | 4.5 ± 0.6 | 1.000 |
Time to endoscopy (hours) | 10.4 ± 11.3 | 10.6 ± 9.9 | 0.904 |
PRBC BT(mL) | 907.4 ± 1109.7 | 1064.8 ± 1003.8 | 0.863 |
Ulcer size (cm) | 1.1 ± 0.7 | 0.9 ± 0.6 | 0.506 |
Multiple ulcers, n (%) | 7(25.9) | 9(33.3) | 0.182 |
Forrest classification Ia/Ib/IIa/IIb | 0/18/2/7 | 0/18/2/7 | 1.000 |
Re-bleeding, n (%) | 3(11.1) | 3 (11.1) | 1.000 |
Surgery, n (%) | 0 | 0 | 1.000 |
Hospital stay (days) | 5.7 ± 5.6 | 11.7 ± 8.6 | 0.031* |
Mortality, n (%), bleeding related and other causes | 0/0 | 0/1 (3.7) | 1.000 |